NCT06120283 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06120283
Title	BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	BeiGene
Indications	endometrial cancer lung non-small cell carcinoma Her2-receptor negative breast cancer breast cancer ovarian cancer Advanced Solid Tumor
Therapies	BGB-43395 BGB-43395 + Elacestrant BGB-43395 + Letrozole BGB-43395 + Fulvestrant
Age Groups:	adult \| senior
Covered Countries	USA \| NZL \| FRA \| BRA \| AUS

NCT06120283
Clinical Trial Detail